Detailed Information
Cited 3 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
Health-related quality of life for pembrolizumab (pembro) plus ipilimumab (ipi) versus pembro plus placebo in patients with metastatic NSCLC with PD-L1 tumor proportion score >= 50%: KEYNOTE-598.
- Authors
- Sendur, MN[Sendur, Mehmet Nahit]; Reck, M[Reck, Martin]; Rodriguez-Abreu, D[Rodriguez-Abreu, Delvys]; Park, K[Park, Keunchil]; Lee, DH[Lee, Dae Ho]; Cicin, I[Cicin, Irfan]; Yumuk, PF[Yumuk, Perran Fulden]; Orlandi, FJ[Orlandi, Francisco J.]; Leal, TA[Leal, Ticiana A.]; Molinier, O[Molinier, Olivier]; Soparattanapaisarn, N[Soparattanapaisarn, Nopadol]; Langleben, A[Langleben, Adrian]; Califano, R[Califano, Raffaele]; Medgyasszay, B[Medgyasszay, Balazs]; Hsia, TC[Hsia, Te-Chun]; Otterson, GA[Otterson, Gregory Alan]; Xu, L[Xu, Lu]; Burke, TA[Burke, Thomas A.]; Samkari, A[Samkari, Ayman]; Boyer, MJ[Boyer, Michael J.]
- Issue Date
- 20-May-2021
- Publisher
- LIPPINCOTT WILLIAMS & WILKINS
- Citation
- JOURNAL OF CLINICAL ONCOLOGY, v.39, no.15
- Indexed
- SCIE
SCOPUS
- Journal Title
- JOURNAL OF CLINICAL ONCOLOGY
- Volume
- 39
- Number
- 15
- ISSN
- 0732-183X
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.